Z-100, an immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis strain Aoyama B, augments anti-tumor activities of X-ray irradiation against B16 melanoma in association with the improvement of type 1T cell responses.
In this study, the effects of combination therapy consisting of X-ray irradiation and Z-100 on the survival time of C57BL/6 mice inoculated with B16F10 melanoma were investigated. Survival time was significantly prolonged in B16F10 melanoma-bearing mice treated with the X-ray irradiation (5 Gy) and Z-100 (10 mg/kg s.c.) combination therapy compared with mice irradiated with X-rays alone. The weight of primary tumors and number of metastatic colonies were also significantly suppressed by the combination therapy compared with that in the X-ray irradiation group. These results indicated that Z-100 could enhance the anti-tumor effects of radiotherapy against B16F10 melanoma. On the other hand, the survival time of CD4 knockout mice bearing the same tumors was not prolonged by the combination therapy compared with mice irradiated with X-rays alone, suggesting that CD4+ cells are partly involved in augmentation of the anti-tumor effect of radiotherapy by Z-100. In addition, type 1 cytokine (IL-2, IFN-gamma) production was significantly increased and type 2 cytokine (IL-4, IL-10) production was significantly suppressed in the tumor-bearing mice treated with the combination therapy compared with the X-ray irradiation group. Moreover, interleukin-12 production by CD11c+ cells was also significantly increased in mice treated with the combination therapy compared with the X-ray irradiation group. These results indicate that Z-100 augmented the anti-tumor effects of X-ray irradiation. Moreover, we demonstrated that the effects of Z-100 were expressed at least in part, by the improvement of the T cell responses from type 2-dominant to type 1-dominant via up-regulation of IL-12 production.
Oka
Hideki
H
Central Research Laboratories, Zeria Pharmaceutical Co. Ltd., 2512-1 Oshikiri, Kohnan-machi, Ohsato-gun, Saitama 360-0111, Japan. hideki-oka@zeria.co.jp
Sasaki
Hidetaka
H
Shiraishi
Yumiko
Y
Emori
Yutaka
Y
Yoshinaga
Koji
K
Takei
Mineo
M
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D039521:CD11c Antigen / Q000187:drug effects; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D003131:Combined Modality Therapy; D016207:Cytokines / Q000096:biosynthesis; D007202:Indicators and Reagents; D018664:Interleukin-12 / Q000096:biosynthesis; D008055:Lipids / Q000494:pharmacology*; D008297:Male; D008351:Mannans / Q000494:pharmacology*; D008546:Melanoma, Experimental / Q000532:radiotherapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000378:metabolism*; D009368:Neoplasm Transplantation; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology*; D018417:Th1 Cells / Q000187:drug effects* / Q000528:radiation effects*
D000276:Adjuvants, Immunologic; D039521:CD11c Antigen; D016207:Cytokines; D007202:Indicators and Reagents; D008055:Lipids; D008351:Mannans; D011838:Radiation-Sensitizing Agents; C031208:specific substance maruyama; D018664:Interleukin-12